Clinical News – July ’16
Medicinal Cannabis Cannabidiol (CBD) Oil now available Australia wide
All Australians now have access to medical Cannabidol Oil (CBD) if sold as a dietary supplement with zero therapeutic value.
Full spectrum Hemp Oil has demonstrated potential neuroprotective and neurogenic effects. Its anti-cancer properties are currently being investigated by several academic research centres around the globe.
Unlike THC, CBD does not alter the mood or mind. While this makes CBD a poor choice for recreational users, it gives the compound a significant advantage of being accepted within mainstream medicine, since health professionals prefer treatments with minimal side effects.
Below are some trusted & Verified Australian Suppliers of genuine CBD Oil:
This is an exciting time for all Australians with this natural therapy now available Australia wide.
Did you know that some vaccines have age limits?
hepatitis B vaccines
Paediatric hepatitis B formulations – given up to 19 years of age.
Adult hepatitis B vaccine formulations – given from ≥ 20 years of age.
Diptheria, tetanus, pertussis (dTpa/DTPa) formulations
Infanrix and Tripacel formulations – given up to ≤ 10 years of age.
Boostrix and Adacel formulations – given from ≥ 10 years of age.
Meningococcal C vaccine
Menitorix (Men C and Hib) – given up to the 10th birthday.
– For people over this age, provide a monovalent conjugate meningococcal C vaccine (currently NeisVac-C).
Combination measles, mumps, rubella and varicella (MMRV) vaccines
Priorix Tetra and Proquad (MMR and Varicella) – given up to the 14th birthday.
– For people over this age, provide a separate MMR and varicella vaccine using separate syringes and injection sites.
For more information, refer to the relevant section of The Australian Immunisation Handbook 10th Edition 2013 (updated online June 2015).
Source: Northern Sydney Public Health Unit
Interruption to supply of Bexsero (meningococcal B vaccine)
NSW Health has advised that the vaccine supplier GSK is currently experiencing an interruption to the supply of Bexsero (meningococcal B vaccine) to the Australian private market. GSK is working to ensure the timely re-supply of Bexsero to the Australian market, and apologises for the delay. GSK will provide an update regarding the availability of Bexsero by the end of September 2016.